PERIPHERAL T-CELL LYMPHOMA
Clinical trials for PERIPHERAL T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PERIPHERAL T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a Five-Drug combo tame a tough lymphoma without standard chemo?
Disease control Not yet recruitingThis phase 2 trial is testing whether a combination of five drugs—chidamide, azacitidine, prednisone, cyclophosphamide, and thalidomide—can help people with peripheral T-cell lymphoma (PTCL) who are unable to tolerate standard chemotherapy. The study will enroll 58 adults with PT…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for hard-to-treat lymphoma: experimental drug enters phase 2 trial
Disease control Not yet recruitingThis study tests a new drug called BR101801 in 44 people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or not responded to standard treatments. The goal is to see if the drug can shrink tumors and how safe it is. Participants will receive the dru…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for rare blood cancer: drug cocktail targets resistant lymphoma
Disease control Not yet recruitingThis study tests whether combining tazemetostat with either linperlisib or golidocitinib can safely shrink tumors in people with relapsed or refractory peripheral T-cell lymphoma. About 48 adults who have already tried at least one other treatment will receive the drugs by mouth.…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC